A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease
Authors:
- Emma Louise RobinsonEmma Louise Robinson
- Clarissa Pedrosa da Costa GomesCGClarissa Pedrosa da Costa Gomes
- Ines PotočnjakIPInes Potočnjak
- Jan HellemansJHJan Hellemans
- Fay BetsouFBFay Betsou
- David de Gonzalo-CalvoDGDavid de Gonzalo-Calvo
- Monika StollMSMonika Stoll
- Mehmet Birhan YilmazMYMehmet Birhan Yilmaz
- Bence ÁggBÁBence Ágg
- Dimitris BeisDimitris Beis
- Maria Carmo-FonsecaMCMaria Carmo-Fonseca
- Francisco J. EnguitaFrancisco J. Enguita
Open Access
- 18 May 2020
- journal article
- research article
- Published by MDPI AG in Non-Coding RNA
- Vol. 6 (2) , 17
Abstract
The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1–4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.Keywords
Funding Information
- Horizon 2020 Framework Programme (CA17129)
This publication has 46 references indexed in Scilit:
- Expanding the functional role of miRNAs in the establishment of permanent atrial fibrillationInternational Journal of Cardiology, 2016
- Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulationNature Medicine, 2016
- Inferring active regulatory networks from gene expression data using a combination of prior knowledge and enrichment analysisBMC Bioinformatics, 2016
- Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular DysfunctionCirculation, 2015
- Sex and gender issues in multiple sclerosisTherapeutic Advances in Neurological Disorders, 2013
- EATRIS, a European initiative to boost translational biomedical research.2013
- MicroRNA Profiling Identifies MicroRNA-155 as an Adverse Mediator of Cardiac Injury and Dysfunction During Acute Viral MyocarditisCirculation Research, 2012
- Assessing Reproductive Status/Stages in MiceCurrent Protocols in Neuroscience, 2009
- Twist-1 Is a PPARδ-Inducible, Negative-Feedback Regulator of PGC-1α in Brown Fat MetabolismCell, 2009
- NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart FailureJournal of Biological Chemistry, 2008